ES2605801T3 - Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia - Google Patents

Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia Download PDF

Info

Publication number: ES2605801T3
Authority: ES; Spain
Prior art keywords: fxa; antidote; factor; seq; inhibitor
Prior art date: 2009-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES10737699.8T

Other languages

English (en)

Spanish (es)

Inventor

Uma Sinha

Genmin Lu

Athiwat Hutchaleelaha

Stanley J. Hollenbach

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Portola Pharmaceuticals LLC

Original Assignee

Portola Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-15

Filing date

2010-07-14

Publication date

2017-03-16

2010-07-14 Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC

2017-03-16 Application granted granted Critical

2017-03-16 Publication of ES2605801T3 publication Critical patent/ES2605801T3/es

Status Active legal-status Critical Current

2030-07-14 Anticipated expiration legal-status Critical

Links

239000000203 mixture Substances 0.000 title claims abstract description 100
238000009472 formulation Methods 0.000 title claims abstract description 64
229940123583 Factor Xa inhibitor Drugs 0.000 title claims abstract description 48
230000000740 bleeding effect Effects 0.000 title claims abstract description 41
230000002265 prevention Effects 0.000 title claims abstract description 19
239000000729 antidote Substances 0.000 title description 421
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 171
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 135
241000282414 Homo sapiens Species 0.000 claims abstract description 132
238000001990 intravenous administration Methods 0.000 claims abstract description 111
229920001184 polypeptide Polymers 0.000 claims abstract description 110
238000001802 infusion Methods 0.000 claims abstract description 59
239000007924 injection Substances 0.000 claims abstract description 56
238000002347 injection Methods 0.000 claims abstract description 56
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 45
108010074860 Factor Xa Proteins 0.000 claims abstract description 42
239000003146 anticoagulant agent Substances 0.000 claims abstract description 42
229940127219 anticoagulant drug Drugs 0.000 claims abstract description 38
230000002829 reductive effect Effects 0.000 claims abstract description 38
230000002947 procoagulating effect Effects 0.000 claims abstract description 33
238000002560 therapeutic procedure Methods 0.000 claims abstract description 33
230000009467 reduction Effects 0.000 claims abstract description 24
108010014806 prothrombinase complex Proteins 0.000 claims abstract description 16
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
238000000034 method Methods 0.000 claims description 145
239000003112 inhibitor Substances 0.000 claims description 144
KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 89
229960001148 rivaroxaban Drugs 0.000 claims description 87
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 80
229960000610 enoxaparin Drugs 0.000 claims description 61
229950011103 betrixaban Drugs 0.000 claims description 43
XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical group C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims description 43
-1 otamixabán Chemical compound 0.000 claims description 34
229940127215 low-molecular weight heparin Drugs 0.000 claims description 31
QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 27
229960003886 apixaban Drugs 0.000 claims description 27
239000003055 low molecular weight heparin Substances 0.000 claims description 27
108010000499 Thromboplastin Proteins 0.000 claims description 24
102000002262 Thromboplastin Human genes 0.000 claims description 24
KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical group O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 19
229960001318 fondaparinux Drugs 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 12
MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 claims description 9
HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims description 5
229960000622 edoxaban Drugs 0.000 claims description 5
230000037361 pathway Effects 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
229940087051 fragmin Drugs 0.000 claims description 4
NPBKHEMDWREFJJ-UHFFFAOYSA-N 2-[(7-carbamimidoylnaphthalen-2-yl)methyl-[4-(1-ethanimidoylpiperidin-4-yl)oxyphenyl]sulfamoyl]acetic acid Chemical compound C1CN(C(=N)C)CCC1OC1=CC=C(N(CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)S(=O)(=O)CC(O)=O)C=C1 NPBKHEMDWREFJJ-UHFFFAOYSA-N 0.000 claims description 3
IJNIQYINMSGIPS-UHFFFAOYSA-N darexaban Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC(O)=C1NC(=O)C1=CC=C(N2CCN(C)CCC2)C=C1 IJNIQYINMSGIPS-UHFFFAOYSA-N 0.000 claims description 3
QQBKAVAGLMGMHI-WIYYLYMNSA-N eribaxaban Chemical compound N1([C@H](C[C@H](C1)OC)C(=O)NC=1C(=CC(=CC=1)N1C(C=CC=C1)=O)F)C(=O)NC1=CC=C(Cl)C=C1 QQBKAVAGLMGMHI-WIYYLYMNSA-N 0.000 claims description 3
LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 claims 1
GEHAEMCVKDPMKO-HXUWFJFHSA-N 1-[1-[(2s)-3-(6-chloronaphthalen-2-yl)sulfonyl-2-hydroxypropanoyl]piperidin-4-yl]-1,3-diazinan-2-one Chemical compound O=C([C@@H](CS(=O)(=O)C=1C=C2C=CC(Cl)=CC2=CC=1)O)N(CC1)CCC1N1CCCNC1=O GEHAEMCVKDPMKO-HXUWFJFHSA-N 0.000 claims 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 150
108090000623 proteins and genes Proteins 0.000 description 128
210000002381 plasma Anatomy 0.000 description 121
230000000694 effects Effects 0.000 description 113
210000004027 cell Anatomy 0.000 description 105
102000040430 polynucleotide Human genes 0.000 description 87
239000002157 polynucleotide Substances 0.000 description 87
108091033319 polynucleotide Proteins 0.000 description 87
102000004169 proteins and genes Human genes 0.000 description 86
235000001014 amino acid Nutrition 0.000 description 80
210000004369 blood Anatomy 0.000 description 80
239000008280 blood Substances 0.000 description 80
235000018102 proteins Nutrition 0.000 description 79
230000027455 binding Effects 0.000 description 74
229940024606 amino acid Drugs 0.000 description 73
150000001413 amino acids Chemical class 0.000 description 71
241000700159 Rattus Species 0.000 description 56
230000010100 anticoagulation Effects 0.000 description 55
208000032843 Hemorrhage Diseases 0.000 description 52
230000014509 gene expression Effects 0.000 description 47
239000003981 vehicle Substances 0.000 description 46
230000015271 coagulation Effects 0.000 description 44
238000005345 coagulation Methods 0.000 description 44
229940075522 antidotes Drugs 0.000 description 40
108090000317 Chymotrypsin Proteins 0.000 description 37
229960002376 chymotrypsin Drugs 0.000 description 37
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
208000034158 bleeding Diseases 0.000 description 35
239000013598 vector Substances 0.000 description 33
125000003729 nucleotide group Chemical group 0.000 description 31
108020004414 DNA Proteins 0.000 description 30
125000000539 amino acid group Chemical group 0.000 description 30
108020004459 Small interfering RNA Proteins 0.000 description 29
239000003795 chemical substances by application Substances 0.000 description 29
239000012634 fragment Substances 0.000 description 29
238000000338 in vitro Methods 0.000 description 29
150000007523 nucleic acids Chemical class 0.000 description 29
108090000190 Thrombin Proteins 0.000 description 28
230000004048 modification Effects 0.000 description 28
238000012986 modification Methods 0.000 description 28
229960004072 thrombin Drugs 0.000 description 28
108091032973 (ribonucleotides)n+m Proteins 0.000 description 27
239000002773 nucleotide Substances 0.000 description 27
238000007792 addition Methods 0.000 description 26
230000005764 inhibitory process Effects 0.000 description 26
238000005259 measurement Methods 0.000 description 26
102000039446 nucleic acids Human genes 0.000 description 24
108020004707 nucleic acids Proteins 0.000 description 24
239000000523 sample Substances 0.000 description 24
238000012360 testing method Methods 0.000 description 23
230000029087 digestion Effects 0.000 description 22
230000014508 negative regulation of coagulation Effects 0.000 description 22
238000011282 treatment Methods 0.000 description 22
241001465754 Metazoa Species 0.000 description 21
230000002429 anti-coagulating effect Effects 0.000 description 21
230000003197 catalytic effect Effects 0.000 description 21
238000001727 in vivo Methods 0.000 description 21
230000003993 interaction Effects 0.000 description 20
238000006722 reduction reaction Methods 0.000 description 20
108010094028 Prothrombin Proteins 0.000 description 19
102100027378 Prothrombin Human genes 0.000 description 19
108091007433 antigens Proteins 0.000 description 19
102000036639 antigens Human genes 0.000 description 19
238000003556 assay Methods 0.000 description 19
239000003153 chemical reaction reagent Substances 0.000 description 19
150000001875 compounds Chemical class 0.000 description 19
238000012937 correction Methods 0.000 description 19
239000012528 membrane Substances 0.000 description 19
229940039716 prothrombin Drugs 0.000 description 19
235000002639 sodium chloride Nutrition 0.000 description 19
239000000427 antigen Substances 0.000 description 18
230000002401 inhibitory effect Effects 0.000 description 18
108060003951 Immunoglobulin Proteins 0.000 description 17
230000008859 change Effects 0.000 description 17
102000018358 immunoglobulin Human genes 0.000 description 17
239000002502 liposome Substances 0.000 description 17
108010013773 recombinant FVIIa Proteins 0.000 description 17
230000002441 reversible effect Effects 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 16
210000004978 chinese hamster ovary cell Anatomy 0.000 description 16
210000004602 germ cell Anatomy 0.000 description 16
102000007327 Protamines Human genes 0.000 description 15
108010007568 Protamines Proteins 0.000 description 15
230000002950 deficient Effects 0.000 description 15
150000003904 phospholipids Chemical class 0.000 description 15
239000000126 substance Substances 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 14
108090000790 Enzymes Proteins 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 14
102000012479 Serine Proteases Human genes 0.000 description 14
108010022999 Serine Proteases Proteins 0.000 description 14
229940088598 enzyme Drugs 0.000 description 14
239000000693 micelle Substances 0.000 description 14
230000036470 plasma concentration Effects 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
238000006467 substitution reaction Methods 0.000 description 14
108010014173 Factor X Proteins 0.000 description 13
241000282412 Homo Species 0.000 description 13
208000007536 Thrombosis Diseases 0.000 description 13
239000002671 adjuvant Substances 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
239000003937 drug carrier Substances 0.000 description 13
229920000669 heparin Polymers 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 13
241000894007 species Species 0.000 description 13
239000000725 suspension Substances 0.000 description 13
241000124008 Mammalia Species 0.000 description 12
230000004087 circulation Effects 0.000 description 12
239000003550 marker Substances 0.000 description 12
238000006386 neutralization reaction Methods 0.000 description 12
230000003472 neutralizing effect Effects 0.000 description 12
229920001223 polyethylene glycol Polymers 0.000 description 12
150000003384 small molecules Chemical class 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 11
230000001580 bacterial effect Effects 0.000 description 11
238000007820 coagulation assay Methods 0.000 description 11
230000000295 complement effect Effects 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
210000004408 hybridoma Anatomy 0.000 description 11
230000035772 mutation Effects 0.000 description 11
239000013612 plasmid Substances 0.000 description 11
230000008569 process Effects 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
241000196324 Embryophyta Species 0.000 description 10
239000002202 Polyethylene glycol Substances 0.000 description 10
230000001588 bifunctional effect Effects 0.000 description 10
238000003776 cleavage reaction Methods 0.000 description 10
230000035602 clotting Effects 0.000 description 10
230000001419 dependent effect Effects 0.000 description 10
230000006870 function Effects 0.000 description 10
125000005647 linker group Chemical group 0.000 description 10
239000008194 pharmaceutical composition Substances 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
229940048914 protamine Drugs 0.000 description 10
230000007017 scission Effects 0.000 description 10
239000000758 substrate Substances 0.000 description 10
230000002459 sustained effect Effects 0.000 description 10
238000012546 transfer Methods 0.000 description 10
230000009261 transgenic effect Effects 0.000 description 10
230000003612 virological effect Effects 0.000 description 10
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 9
108700005091 Immunoglobulin Genes Proteins 0.000 description 9
239000001110 calcium chloride Substances 0.000 description 9
229910001628 calcium chloride Inorganic materials 0.000 description 9
235000011148 calcium chloride Nutrition 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
239000013604 expression vector Substances 0.000 description 9
230000000670 limiting effect Effects 0.000 description 9
150000002632 lipids Chemical class 0.000 description 9
238000002493 microarray Methods 0.000 description 9
229920000642 polymer Polymers 0.000 description 9
238000001356 surgical procedure Methods 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
241000393496 Electra Species 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
241000700605 Viruses Species 0.000 description 8
230000004913 activation Effects 0.000 description 8
230000021615 conjugation Effects 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
230000023597 hemostasis Effects 0.000 description 8
230000003285 pharmacodynamic effect Effects 0.000 description 8
239000000047 product Substances 0.000 description 8
239000001509 sodium citrate Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
102400000069 Activation peptide Human genes 0.000 description 7
101800001401 Activation peptide Proteins 0.000 description 7
241000282693 Cercopithecidae Species 0.000 description 7
UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 7
102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 7
101000880344 Homo sapiens Elongation factor G, mitochondrial Proteins 0.000 description 7
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
229960003767 alanine Drugs 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
239000000872 buffer Substances 0.000 description 7
235000014113 dietary fatty acids Nutrition 0.000 description 7
230000008030 elimination Effects 0.000 description 7
238000003379 elimination reaction Methods 0.000 description 7
239000000194 fatty acid Substances 0.000 description 7
229930195729 fatty acid Natural products 0.000 description 7
238000001476 gene delivery Methods 0.000 description 7
229960002897 heparin Drugs 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
230000036961 partial effect Effects 0.000 description 7
210000001236 prokaryotic cell Anatomy 0.000 description 7
238000011160 research Methods 0.000 description 7
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
238000013519 translation Methods 0.000 description 7
230000014616 translation Effects 0.000 description 7
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 6
229920000936 Agarose Polymers 0.000 description 6
241000283690 Bos taurus Species 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241000238631 Hexapoda Species 0.000 description 6
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
241001529936 Murinae Species 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
241001494479 Pecora Species 0.000 description 6
102000035195 Peptidases Human genes 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 6
239000004365 Protease Substances 0.000 description 6
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
235000004279 alanine Nutrition 0.000 description 6
230000000692 anti-sense effect Effects 0.000 description 6
239000011324 bead Substances 0.000 description 6
238000010241 blood sampling Methods 0.000 description 6
238000001514 detection method Methods 0.000 description 6
210000003527 eukaryotic cell Anatomy 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
229960000485 methotrexate Drugs 0.000 description 6
230000003278 mimic effect Effects 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
210000004623 platelet-rich plasma Anatomy 0.000 description 6
229950008679 protamine sulfate Drugs 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
230000010076 replication Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
230000001177 retroviral effect Effects 0.000 description 6
229960001153 serine Drugs 0.000 description 6
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
239000003868 thrombin inhibitor Substances 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
102000007469 Actins Human genes 0.000 description 5
108010085238 Actins Proteins 0.000 description 5
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 5
206010053567 Coagulopathies Diseases 0.000 description 5
108010090444 Innovin Proteins 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
241000282560 Macaca mulatta Species 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
102100024952 Protein CBFA2T1 Human genes 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
101100226845 Strongylocentrotus purpuratus EGF2 gene Proteins 0.000 description 5
238000000692 Student's t-test Methods 0.000 description 5
229940122388 Thrombin inhibitor Drugs 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
108090000631 Trypsin Proteins 0.000 description 5
102000004142 Trypsin Human genes 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
230000023555 blood coagulation Effects 0.000 description 5
150000001718 carbodiimides Chemical class 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
239000003431 cross linking reagent Substances 0.000 description 5
238000009826 distribution Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
238000000099 in vitro assay Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
239000003446 ligand Substances 0.000 description 5
238000002703 mutagenesis Methods 0.000 description 5
231100000350 mutagenesis Toxicity 0.000 description 5
239000000816 peptidomimetic Substances 0.000 description 5
238000012453 sprague-dawley rat model Methods 0.000 description 5
210000000130 stem cell Anatomy 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
239000012588 trypsin Substances 0.000 description 5
238000001262 western blot Methods 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 4
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 4
108090000935 Antithrombin III Proteins 0.000 description 4
108090001008 Avidin Proteins 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
241000283707 Capra Species 0.000 description 4
241000699800 Cricetinae Species 0.000 description 4
101150074155 DHFR gene Proteins 0.000 description 4
241000702421 Dependoparvovirus Species 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 4
108700019146 Transgenes Proteins 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
238000001261 affinity purification Methods 0.000 description 4
238000005576 amination reaction Methods 0.000 description 4
210000004102 animal cell Anatomy 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
239000011616 biotin Substances 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
238000011088 calibration curve Methods 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000032050 esterification Effects 0.000 description 4
238000005886 esterification reaction Methods 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
239000007850 fluorescent dye Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
238000005342 ion exchange Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
229960003299 ketamine Drugs 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
239000000843 powder Substances 0.000 description 4
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
238000011002 quantification Methods 0.000 description 4
238000000611 regression analysis Methods 0.000 description 4
238000004088 simulation Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000012032 thrombin generation assay Methods 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
210000005253 yeast cell Anatomy 0.000 description 4
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
241000710929 Alphavirus Species 0.000 description 3
102000015081 Blood Coagulation Factors Human genes 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
150000008574 D-amino acids Chemical class 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
206010014522 Embolism venous Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
108010048049 Factor IXa Proteins 0.000 description 3
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
102000001554 Hemoglobins Human genes 0.000 description 3
108010054147 Hemoglobins Proteins 0.000 description 3
238000011992 High performance liquid chromatography with tandem mass spectrometry Methods 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
244000061176 Nicotiana tabacum Species 0.000 description 3
235000002637 Nicotiana tabacum Nutrition 0.000 description 3
108010018682 PRT064445 Proteins 0.000 description 3
102000003827 Plasma Kallikrein Human genes 0.000 description 3
108090000113 Plasma Kallikrein Proteins 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
241000288906 Primates Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
101001045455 Proteus vulgaris Antitoxin HigA Proteins 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010039491 Ricin Proteins 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
108090000787 Subtilisin Proteins 0.000 description 3
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000012190 activator Substances 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000003024 amidolytic effect Effects 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
229940127090 anticoagulant agent Drugs 0.000 description 3
239000003114 blood coagulation factor Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
229910001424 calcium ion Inorganic materials 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003593 chromogenic compound Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
239000003636 conditioned culture medium Substances 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
238000010219 correlation analysis Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
210000003191 femoral vein Anatomy 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
230000005714 functional activity Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
210000004731 jugular vein Anatomy 0.000 description 3
238000002372 labelling Methods 0.000 description 3
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000000399 orthopedic effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000035699 permeability Effects 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
229920000058 polyacrylate Polymers 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000003805 procoagulant Substances 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000026683 transduction Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
230000008733 trauma Effects 0.000 description 3
208000004043 venous thromboembolism Diseases 0.000 description 3
239000002821 viper venom Substances 0.000 description 3
150000003721 vitamin K derivatives Chemical class 0.000 description 3
229960005080 warfarin Drugs 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 2
AGRCGQSFFMCBRE-ZEQRLZLVSA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid Chemical compound C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 AGRCGQSFFMCBRE-ZEQRLZLVSA-N 0.000 description 2
PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 2
ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
241001539917 Actina Species 0.000 description 2
102000013142 Amylases Human genes 0.000 description 2
108010065511 Amylases Proteins 0.000 description 2
244000105975 Antidesma platyphyllum Species 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
102000004411 Antithrombin III Human genes 0.000 description 2
102100022977 Antithrombin-III Human genes 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
241000282465 Canis Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
208000034656 Contusions Diseases 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
108010054265 Factor VIIa Proteins 0.000 description 2
241000233866 Fungi Species 0.000 description 2
101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
108010007267 Hirudins Proteins 0.000 description 2
102000007625 Hirudins Human genes 0.000 description 2
101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
101100160997 Mus musculus Rchy1 gene Proteins 0.000 description 2
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
241000272144 Naja atra Species 0.000 description 2
102100036946 Nck-associated protein 5 Human genes 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241001504519 Papio ursinus Species 0.000 description 2
241000235648 Pichia Species 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
108020005038 Terminator Codon Proteins 0.000 description 2
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
RDFCSSHDJSZMTQ-ZDUSSCGKSA-N Tos-Lys-CH2Cl Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 RDFCSSHDJSZMTQ-ZDUSSCGKSA-N 0.000 description 2
108020004566 Transfer RNA Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
229960002054 acenocoumarol Drugs 0.000 description 2
VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
235000019418 amylase Nutrition 0.000 description 2
229940025131 amylases Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
229960005348 antithrombin iii Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000008901 benefit Effects 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
YXLGWNWVIGXGME-NRFANRHFSA-N benzyl n-[2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[(4-methyl-2-oxochromen-7-yl)amino]pentanoyl]amino]-2-oxoethyl]amino]-2-oxoethyl]carbamate Chemical compound O=C([C@H](CCCN=C(N)N)NC1=CC=2OC(=O)C=C(C=2C=C1)C)NC(=O)CNC(=O)CNC(=O)OCC1=CC=CC=C1 YXLGWNWVIGXGME-NRFANRHFSA-N 0.000 description 2
JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 2
108010055460 bivalirudin Proteins 0.000 description 2
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229960002713 calcium chloride Drugs 0.000 description 2
108090001015 cancer procoagulant Proteins 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
108020001778 catalytic domains Proteins 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
239000002458 cell surface marker Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
239000000562 conjugate Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
235000001671 coumarin Nutrition 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000012631 diagnostic technique Methods 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
208000001780 epistaxis Diseases 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
229940011411 erythrosine Drugs 0.000 description 2
239000004174 erythrosine Substances 0.000 description 2
235000012732 erythrosine Nutrition 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
235000009424 haa Nutrition 0.000 description 2
230000003862 health status Effects 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229940006607 hirudin Drugs 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
229960002885 histidine Drugs 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000010354 integration Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
FIBJDTSHOUXTKV-BRHMIFOHSA-N lepirudin Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O FIBJDTSHOUXTKV-BRHMIFOHSA-N 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
229940118179 lovenox Drugs 0.000 description 2
DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000000863 peptide conjugate Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
239000003998 snake venom Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
235000021286 stilbenes Nutrition 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000005460 tetrahydrofolate Substances 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
239000011712 vitamin K Substances 0.000 description 2
229940046010 vitamin k Drugs 0.000 description 2
229940019333 vitamin k antagonists Drugs 0.000 description 2
229940055725 xarelto Drugs 0.000 description 2
PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
AASYSXRGODIQGY-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(CCCCC)N1C(=O)C=CC1=O AASYSXRGODIQGY-UHFFFAOYSA-N 0.000 description 1
MPBMJFQAGBVIDC-UHFFFAOYSA-N 1-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)NC(C(O)=O)CC2=C1 MPBMJFQAGBVIDC-UHFFFAOYSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
JPHGTWWUDOEBRJ-UHFFFAOYSA-N 2-amino-3,4,4a,5-tetrahydro-1h-naphthalene-2-carboxylic acid Chemical compound C1C=CC=C2CC(N)(C(O)=O)CCC21 JPHGTWWUDOEBRJ-UHFFFAOYSA-N 0.000 description 1
FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
QRYXYRQPMWQIDM-UHFFFAOYSA-N 3-benzoyl-3-(2,5-dioxopyrrol-1-yl)-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1(C(=O)C=1C=CC=CC=1)N1C(=O)C=CC1=O QRYXYRQPMWQIDM-UHFFFAOYSA-N 0.000 description 1
YYLQUHNPNCGKJQ-PIKHSQJKSA-N 3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)C(O)C(O)=O YYLQUHNPNCGKJQ-PIKHSQJKSA-N 0.000 description 1
BMUXFZXYGDXKJY-UHFFFAOYSA-N 4-azido-2-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(N=[N+]=[N-])C=C1O BMUXFZXYGDXKJY-UHFFFAOYSA-N 0.000 description 1
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
ZBPYOEMMLMVVQT-UHFFFAOYSA-N 5-chloropyridine-2-carboxamide Chemical compound NC(=O)C1=CC=C(Cl)C=N1 ZBPYOEMMLMVVQT-UHFFFAOYSA-N 0.000 description 1
LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
241000203069 Archaea Species 0.000 description 1
241000228254 Aspergillus restrictus Species 0.000 description 1
101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
102100026031 Beta-glucuronidase Human genes 0.000 description 1
108010028614 BnSO(2)-D-Arg-Gly-Arg-ketothiazole Proteins 0.000 description 1
UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
102100033620 Calponin-1 Human genes 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108020004998 Chloroplast DNA Proteins 0.000 description 1
108020005133 Chloroplast RNA Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
101710112752 Cytotoxin Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
235000000638 D-biotin Nutrition 0.000 description 1
239000011665 D-biotin Substances 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
241000271032 Daboia russelii Species 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
JYGLAHSAISAEAL-UHFFFAOYSA-N Diphenadione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JYGLAHSAISAEAL-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
229940123688 Direct Factor Xa inhibitor Drugs 0.000 description 1
229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108010071241 Factor XIIa Proteins 0.000 description 1
108010080805 Factor XIa Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
108010008488 Glycylglycine Proteins 0.000 description 1
206010019027 Haemothorax Diseases 0.000 description 1
101710153310 Hemoglobin subunit beta-3 Proteins 0.000 description 1
102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
244000207740 Lemna minor Species 0.000 description 1
235000006439 Lemna minor Nutrition 0.000 description 1
241000270322 Lepidosauria Species 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
241000282553 Macaca Species 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010079364 N-glycylalanine Proteins 0.000 description 1
101710204212 Neocarzinostatin Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000233855 Orchidaceae Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282579 Pan Species 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
231100000742 Plant toxin Toxicity 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
235000001855 Portulaca oleracea Nutrition 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241001138501 Salmonella enterica Species 0.000 description 1
240000003946 Saponaria officinalis Species 0.000 description 1
108010084592 Saporins Proteins 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
102100035088 Sodium/calcium exchanger 1 Human genes 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
241000194026 Streptococcus gordonii Species 0.000 description 1
PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
101150052863 THY1 gene Proteins 0.000 description 1
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000235013 Yarrowia Species 0.000 description 1
DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
VUBTYKDZOQNADH-UHFFFAOYSA-N acetyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)=O VUBTYKDZOQNADH-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
239000002776 alpha toxin Substances 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
229940003354 angiomax Drugs 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001858 anti-Xa Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229940090880 ardeparin Drugs 0.000 description 1
229940104697 arixtra Drugs 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
229910001626 barium chloride Inorganic materials 0.000 description 1
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
229940006612 barium citrate Drugs 0.000 description 1
PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004993 binary fission Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
108700021042 biotin binding protein Proteins 0.000 description 1
102000043871 biotin binding protein Human genes 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
NXVYSVARUKNFNF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) 2,3-dihydroxybutanedioate Chemical compound O=C1CCC(=O)N1OC(=O)C(O)C(O)C(=O)ON1C(=O)CCC1=O NXVYSVARUKNFNF-UHFFFAOYSA-N 0.000 description 1
JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000001273 butane Substances 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
229940052299 calcium chloride dihydrate Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
150000001784 cerebrosides Chemical class 0.000 description 1
229940107792 certoparin Drugs 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
229960001307 clorindione Drugs 0.000 description 1
NJDUWAXIURWWLN-UHFFFAOYSA-N clorindione Chemical compound C1=CC(Cl)=CC=C1C1C(=O)C2=CC=CC=C2C1=O NJDUWAXIURWWLN-UHFFFAOYSA-N 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
229940072645 coumadin Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000002574 cystoscopy Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
229960004969 dalteparin Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
229960003828 danaparoid Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical class [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
229940093541 dicetylphosphate Drugs 0.000 description 1
229960001912 dicoumarol Drugs 0.000 description 1
DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
229960000267 diphenadione Drugs 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000002283 elective surgery Methods 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
238000009297 electrocoagulation Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000002297 emergency surgery Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
RGHMPTHWVVRXHW-UHFFFAOYSA-N ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate Chemical compound C1=CC=C2CNC(C(=O)OCC)CC2=C1 RGHMPTHWVVRXHW-UHFFFAOYSA-N 0.000 description 1
229960002822 ethyl biscoumacetate Drugs 0.000 description 1
JCLHQFUTFHUXNN-UHFFFAOYSA-N ethyl biscoumacetate Chemical compound C1=CC=C2OC(=O)C(C(C=3C(OC4=CC=CC=C4C=3O)=O)C(=O)OCC)=C(O)C2=C1 JCLHQFUTFHUXNN-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229940012414 factor viia Drugs 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000005021 gait Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
229940043257 glycylglycine Drugs 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
125000005179 haloacetyl group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
229960003569 hematoporphyrin Drugs 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000054751 human RUNX1T1 Human genes 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
229940095443 innohep Drugs 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007689 inspection Methods 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000006623 intrinsic pathway Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000002523 lectin Substances 0.000 description 1
108010002230 lepirudin Proteins 0.000 description 1
229960004408 lepirudin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000007422 luminescence assay Methods 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229940118019 malondialdehyde Drugs 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
210000005060 membrane bound organelle Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002923 metal particle Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
108091064355 mitochondrial RNA Proteins 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000037230 mobility Effects 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
229960000899 nadroparin Drugs 0.000 description 1
QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
229950009478 otamixaban Drugs 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
239000000123 paper Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960000280 phenindione Drugs 0.000 description 1
NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
229960002429 proline Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
108010012557 prothrombin complex concentrates Proteins 0.000 description 1
239000012264 purified product Substances 0.000 description 1
150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
229960003581 pyridoxal Drugs 0.000 description 1
235000008164 pyridoxal Nutrition 0.000 description 1
239000011674 pyridoxal Substances 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
229940068953 recombinant fviia Drugs 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
229940030915 refludan Drugs 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
108020004418 ribosomal RNA Proteins 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
229940066675 ricinoleate Drugs 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
108010067207 sodium-calcium exchanger 1 Proteins 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
210000001988 somatic stem cell Anatomy 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
229940124547 specific antidotes Drugs 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003461 sulfonyl halides Chemical class 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229940056501 technetium 99m Drugs 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
229960003766 thrombin (human) Drugs 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 description 1
229960005062 tinzaparin Drugs 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
230000004865 vascular response Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
229950009268 zinostatin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

ES10737699.8T 2009-07-15 2010-07-14 Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia Active ES2605801T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22588709P	2009-07-15	2009-07-15
US225887P		2009-07-15
PCT/US2010/042015 WO2011008885A1 (en)	2009-07-15	2010-07-14	Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same

Publications (1)

Publication Number	Publication Date
ES2605801T3 true ES2605801T3 (es)	2017-03-16

Family

ID=42989417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES10737699.8T Active ES2605801T3 (es)	2009-07-15	2010-07-14	Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia

Country Status (8)

Country	Link
US (8)	US9056106B2 (2)
EP (1)	EP2453910B1 (2)
JP (2)	JP6163304B2 (2)
CN (1)	CN102625712B (2)
CA (1)	CA2767858C (2)
ES (1)	ES2605801T3 (2)
PT (1)	PT2453910T (2)
WO (1)	WO2011008885A1 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ572418A (en)	2006-05-05	2011-08-26	Millennium Pharm Inc	Factor xa inhibitors
EP2915564B1 (en) *	2007-09-28	2020-11-04	Portola Pharmaceuticals, Inc.	Antidotes for factor XA inhibitors and methods of using the same
EP3121271B1 (en) *	2009-03-30	2019-07-24	Portola Pharmaceuticals, Inc.	Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) *	2009-07-15	2017-03-16	Portola Pharmaceuticals, Inc.	Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
US8742120B2 (en)	2009-12-17	2014-06-03	Millennium Pharmaceuticals, Inc.	Methods of preparing factor xa inhibitors and salts thereof
CN102762550B (zh)	2009-12-17	2015-04-01	米伦纽姆医药公司	Xa因子抑制剂的盐和结晶形式
CN104254603A (zh) *	2012-02-14	2014-12-31	博尔托拉制药公司	用于制备xa因子抑制剂的重组解毒剂的方法
US20160015793A1 (en)	2012-02-16	2016-01-21	Portola Pharmacueticals, Inc.	Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote
WO2014018120A1 (en) *	2012-07-25	2014-01-30	Catalyst Biosciences, Inc.	Modified factor x polypeptides and uses thereof
FR3000895B1 (fr)	2013-01-11	2017-02-24	Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa	Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
CA2898975C (en) *	2013-01-24	2021-06-15	Portola Pharmaceuticals, Inc.	Inhibition of tissue factor pathway inhibitor with factor xa derivatives
ES2761730T3 (es)	2013-01-31	2020-05-20	Pfizer	Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en)	2013-09-24	2016-08-03	Pfizer Inc.	Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3063170A4 (en) *	2013-11-01	2017-06-28	The Children's Hospital of Philadelphia	Compositions and methods for increasing the half-life of factor xa
BR112016014617A2 (pt) *	2014-01-24	2017-09-19	Pfizer	Variante do fator xa (fxa) e usos da referida variante
US9545383B2 (en)	2014-04-01	2017-01-17	Massachusetts Institute Of Technology	Blood clotting control
EA202190813A1 (ru)	2014-05-26	2021-12-31	Академиш Зикенхёйс Лейден	Прогемостатические белки для лечения кровотечений
US10676731B2 (en)	2014-08-19	2020-06-09	The Children's Hospital Of Philadelphia	Compositions and methods for modulating factor IX function
EP3750556A1 (en)	2014-08-20	2020-12-16	Portola Pharmaceuticals, Inc.	Lyophilized formulations for factor xa antidote
WO2017147522A1 (en)	2016-02-24	2017-08-31	Portola Pharmaceuticals, Inc.	Lyophilized formulations for factor xa antidote
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
PT3472314T (pt) *	2016-06-17	2021-06-18	Alexion Pharma Inc	Preparação de derivados do fator xa
AU2017383232B2 (en)	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
WO2020163685A1 (en) *	2019-02-07	2020-08-13	Portola Pharmaceuticals, Inc.	Methods for treating intracranial hemorrhage and assessing efficacy
US12073926B2 (en)	2020-09-21	2024-08-27	Instrumentation Laboratory Company	Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4754065A (en)	1984-12-18	1988-06-28	Cetus Corporation	Precursor to nucleic acid probe
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE229046T1 (de)	1985-03-30	1987-12-17	Marc Genf/Geneve Ballivet	Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5837249A (en)	1985-04-19	1998-11-17	The Wistar Institute	Method for generating an immunogenic T cell response protective against a virus
US4818700A (en)	1985-10-25	1989-04-04	Phillips Petroleum Company	Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en)	1986-02-18	1989-03-14	Phillips Petroleum Company	Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en)	1987-02-17	1998-04-01	Pharming B.V.	DNA sequences to target proteins to the mammary gland for efficient secretion
US6270961B1 (en)	1987-04-01	2001-08-07	Hyseq, Inc.	Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en)	1987-04-01	1993-04-13	Drmanac Radoje T	Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en)	1987-10-19	1990-05-29	Phillips Petroleum Company	Pichia transformation
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5686073A (en)	1990-05-23	1997-11-11	The University Of Iowa Research Foundation	Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
CA2090126C (en)	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
US5597799A (en)	1990-09-04	1997-01-28	Cor Therapeutics, Inc.	Recombinant agents affecting thrombosis
US5278144A (en)	1990-09-04	1994-01-11	Cor Therapeutics, Inc.	Antithrombosis agents
US5583107A (en)	1990-09-04	1996-12-10	Cor Therapeutics, Inc.	Agents affecting thrombosis and hemostasis
WO1992013878A2 (en)	1991-02-07	1992-08-20	Board Of Trustees Of The University Of Illinois	Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en)	1991-05-17	2004-09-28	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
RU2212899C2 (ru)	1991-09-13	2003-09-27	Чирон Корпорейшн	Hcv иммунореактивные полипептидные композиции
ATE207080T1 (de)	1991-11-25	2001-11-15	Enzon Inc	Multivalente antigen-bindende proteine
EP0571613B1 (en)	1991-12-13	2003-09-17	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE4203965A1 (de)	1992-02-11	1993-08-12	Max Planck Gesellschaft	Antidot fuer hirudin und synthetische thrombininhibitoren
EP0705344B8 (en)	1993-06-24	2006-05-10	Advec Inc.	Adenovirus vectors for gene therapy
US5858659A (en)	1995-11-29	1999-01-12	Affymetrix, Inc.	Polymorphism detection
AU687117B2 (en)	1993-10-25	1998-02-19	Canji, Inc.	Recombinant adenoviral vector and methods of use
US5455338A (en)	1993-11-05	1995-10-03	Zymogenetics, Inc.	DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en)	1993-12-10	1999-09-14	California Institute Of Technology	Nucleic acid mediated electron transfer
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
US5589571A (en)	1994-10-28	1996-12-31	Cor Therapeutics, Inc.	Process for production of inhibited forms of activated blood factors
AT404357B (de)	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
US5968740A (en)	1995-07-24	1999-10-19	Affymetrix, Inc.	Method of Identifying a Base in a Nucleic Acid
US5955349A (en)	1996-08-26	1999-09-21	Zymogenetics, Inc.	Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de)	1996-02-12	1997-08-14	Basf Ag	Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US6200955B1 (en)	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
US5736383A (en)	1996-08-26	1998-04-07	Zymogenetics, Inc.	Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en)	1996-08-02	2004-03-23	Zymogenetics, Inc.	Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv)	1996-12-20	1996-12-20	Pharmacia & Upjohn Ab	A modified coagulation agent
SE9700422D0 (sv)	1997-02-07	1997-02-07	Astra Ab	Single dose inhaler II
US6051563A (en) *	1997-02-12	2000-04-18	U.S. Bioscience, Inc.	Methods for the administration of amifostine and related compounds
AT405516B (de)	1997-02-27	1999-09-27	Immuno Ag	Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de)	1997-02-27	1999-09-27	Immuno Ag	Faktor x-deletionsmutanten und analoge davon
AU6673898A (en)	1997-03-07	1998-09-22	Washington University	Factor x variant
JPH1149800A (ja)	1997-06-05	1999-02-23	Fujimori Kogyo Kk	アンヒドロトロンビンの合成方法
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6322788B1 (en)	1998-08-20	2001-11-27	Stanley Arthur Kim	Anti-bacterial antibodies and methods of use
AU1728800A (en)	1998-11-18	2000-06-05	Genentech Inc.	Antibody variants with higher binding affinity compared to parent antibodies
WO2000054787A1 (en)	1999-03-16	2000-09-21	The Children's Hospital Of Philadelphia	Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en)	1999-03-17	2003-09-23	The Regents Of The University Of Michigan	Protamine fragment compositions and methods of use
US6258559B1 (en)	1999-03-22	2001-07-10	Zymogenetics, Inc.	Method for producing proteins in transformed Pichia
US6939545B2 (en)	1999-04-28	2005-09-06	Genetics Institute, Llc	Composition and method for treating inflammatory disorders
EP1095933A1 (en)	1999-10-30	2001-05-02	Aventis Pharma Deutschland GmbH	Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
WO2001064642A2 (en)	2000-02-29	2001-09-07	Cor Therapeutics, Inc.	Benzamides and related inhibitors of factor xa
WO2001068605A1 (en)	2000-03-13	2001-09-20	Pharmacia Corporation	Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
ATE549347T1 (de)	2000-09-08	2012-03-15	Schering Corp	Gene von säugetiere, und damit verbundene reagentien, methoden
US7070740B1 (en)	2000-09-28	2006-07-04	Beckman Coulter, Inc.	Method and apparatus for processing biomolecule arrays
US20030064414A1 (en)	2001-03-30	2003-04-03	Benecky Michael J.	Rapid assessment of coagulation activity in whole blood
WO2002090599A1 (en)	2001-05-09	2002-11-14	Genetic Id, Inc.	Universal microarray system
US6989267B2 (en)	2001-07-02	2006-01-24	Agilent Technologies, Inc.	Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
US20040198660A1 (en)	2002-11-06	2004-10-07	Petersen Lars Christian	Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en)	2003-06-04	2007-07-24	Bristol-Myers Squibb Company	3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
AU2004271800A1 (en)	2003-09-12	2005-03-24	Pfizer Inc.	Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
JP2007527539A (ja)	2004-03-05	2007-09-27	ザスクリプスリサーチインスティテュート	ハイスループットグリカンマイクロアレイ
JP4441336B2 (ja)	2004-06-11	2010-03-31	日本碍子株式会社	マイクロアレイの製造方法
US9223929B2 (en)	2005-03-14	2015-12-29	The California Institute Of Technology	Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en)	2005-03-21	2006-10-10	Los Alamos National Security, Llc	Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (en)	2005-03-22	2006-09-28	The Trustees Of Columbia University In The City Of New York	A liposome-based microarray and methods of use thereof
PE20070717A1 (es)	2005-11-08	2007-08-17	Millennium Pharm Inc	Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
US20070111322A1 (en)	2005-11-15	2007-05-17	Lin-Cheng Yang	Novel method of using inject printing for creating microarrays
MX2008006313A (es)	2005-11-15	2008-11-06	Philadelphia Children Hospital	Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en)	2006-02-21	2007-08-22	CSL Behring GmbH	Coagulation factor X polypeptides with modified activation properties
KR101472765B1 (ko)	2006-12-08	2014-12-15	밀레니엄 파머슈티컬스 인코퍼레이티드	경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
CN105037549B (zh) *	2007-01-11	2018-09-28	诺和诺德公司	抗-kir抗体、制剂及其应用
EP2915564B1 (en) *	2007-09-28	2020-11-04	Portola Pharmaceuticals, Inc.	Antidotes for factor XA inhibitors and methods of using the same
MX2011004907A (es)	2008-11-14	2011-07-29	Portola Pharm Inc	Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
JP5833448B2 (ja)	2008-12-19	2015-12-16	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
EP3121271B1 (en) *	2009-03-30	2019-07-24	Portola Pharmaceuticals, Inc.	Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) *	2009-07-15	2017-03-16	Portola Pharmaceuticals, Inc.	Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
CN104254603A (zh) *	2012-02-14	2014-12-31	博尔托拉制药公司	用于制备xa因子抑制剂的重组解毒剂的方法

2010
- 2010-07-14 ES ES10737699.8T patent/ES2605801T3/es active Active
- 2010-07-14 EP EP10737699.8A patent/EP2453910B1/en active Active
- 2010-07-14 CN CN201080040105.XA patent/CN102625712B/zh active Active
- 2010-07-14 US US12/836,536 patent/US9056106B2/en active Active
- 2010-07-14 WO PCT/US2010/042015 patent/WO2011008885A1/en not_active Ceased
- 2010-07-14 CA CA2767858A patent/CA2767858C/en active Active
- 2010-07-14 PT PT107376998T patent/PT2453910T/pt unknown
- 2010-07-14 JP JP2012520756A patent/JP6163304B2/ja active Active
2014
- 2014-06-30 US US14/320,199 patent/US20150025011A1/en not_active Abandoned
2015
- 2015-08-10 JP JP2015158084A patent/JP2015205933A/ja active Pending
2016
- 2016-07-15 US US15/212,105 patent/US20170014492A1/en not_active Abandoned
2017
- 2017-12-06 US US15/833,520 patent/US10765726B2/en active Active
2020
- 2020-07-30 US US16/943,933 patent/US20210085762A1/en not_active Abandoned
2022
- 2022-01-05 US US17/569,402 patent/US20230000957A1/en not_active Abandoned
2023
- 2023-07-14 US US18/352,637 patent/US20240189401A1/en not_active Abandoned
2024
- 2024-10-08 US US18/909,369 patent/US20250186563A1/en active Pending

Also Published As

Publication number	Publication date
US20250186563A1 (en)	2025-06-12
JP6163304B2 (ja)	2017-07-12
WO2011008885A1 (en)	2011-01-20
US20240189401A1 (en)	2024-06-13
CN102625712B (zh)	2017-07-25
JP2012533552A (ja)	2012-12-27
CA2767858A1 (en)	2011-01-20
CA2767858C (en)	2019-02-12
CN102625712A (zh)	2012-08-01
US20230000957A1 (en)	2023-01-05
US20180236049A1 (en)	2018-08-23
US20210085762A1 (en)	2021-03-25
JP2015205933A (ja)	2015-11-19
PT2453910T (pt)	2016-12-07
US10765726B2 (en)	2020-09-08
US20110015128A1 (en)	2011-01-20
US20170014492A1 (en)	2017-01-19
US9056106B2 (en)	2015-06-16
US20150025011A1 (en)	2015-01-22
EP2453910A1 (en)	2012-05-23
EP2453910B1 (en)	2016-08-31

Publication	Publication Date	Title
ES2605801T3 (es)	2017-03-16	Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
ES2597436T3 (es)	2017-01-18	Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
ES2607935T3 (es)	2017-04-04	Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
HK40052336A (en)	2022-01-21	Antidotes for factor xa inhibitors and methods of using the same
HK40022611A (en)	2020-11-20	Antidotes for factor xa inhibitors and methods of using the same
HK1236989A1 (en)	2018-04-06	Antidotes for factor xa inhibitors and methods of using the same
HK1229844A1 (en)	2017-11-24	Antidotes for factor xa inhibitors and methods of using the same
HK1167346B (en)	2017-10-13	Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
HK1229844B (en)	2021-02-19	Antidotes for factor xa inhibitors and methods of using the same
HK1210443B (en)	2021-05-28	Antidotes for factor xa inhibitors and methods of using the same
HK1162584B (en)	2017-12-08	Antidotes for factor xa inhibitors and methods of using the same
HK1172927A (zh)	2013-05-03	用於因子xa抑制剂的解毒剂和其使用方法
HK1143398B (en)	2017-10-06	Antidotes for factor xa inhibitors and methods of using the same